Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3K | 6K | 6K |
| Gross Profit | 0 | 0 | 483 | 4K | 4K |
| Operating Income | 0 | -313K | -448K | -672K | -672K |
| EBITDA | 0 | 0 | -447K | -671K | -876K |
| Net Income | -566K | -142K | -495K | -697K | -911K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.35
+0.57% today
1Y Change
+38.61%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 130 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stimcell Energetics, Inc. (STME) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.35 and up 38.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -782.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -782.4%, free cash flow +2.9% with operating margin 0.0% and ROIC 100.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STME price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STME
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STME Max Drawdown
-47.90%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STME and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.1K
+0.0% YoY
FY Net Income
-$910.8K
-30.6% YoY
Free Cash Flow
-$562.0K
-24.7% YoY
Revenue Growth
+0.0%
EPS Growth
-782.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3K | 6K | 6K |
| Gross Profit | 0 | 0 | 483 | 4K | 4K |
| Operating Income | 0 | -313K | -448K | -672K | -672K |
| EBITDA | 0 | 0 | -447K | -671K | -876K |
| Net Income | -566K | -142K | -495K | -697K | -911K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15K | 43K | 98K | 24K | 24K |
| Total Assets | 21K | 46K | 103K | 41K | 52K |
| Total Liabilities | 1M | 873K | 2M | 2M | 2M |
| Shareholder Equity | -1M | -826K | -2M | -2M | -2M |
| Total Debt | 0 | 313K | 1M | 617K | 617K |
| Net Debt | -15K | 270K | 903K | 592K | 592K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
560K
-24.4% YoY
Capital Expenditures
2K
Free Cash Flow
562K
-24.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
60.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.